Chris A. Rallis - Apr 17, 2023 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A. Rallis
Stock symbol
FENC
Transactions as of
Apr 17, 2023
Transactions value $
-$3,225
Form type
4
Date filed
4/17/2023, 09:25 PM
Previous filing
Mar 3, 2023
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $5K +1.7K +5.3% $2.94 33.8K Apr 17, 2023 Direct F1
transaction FENC Common Shares Tax liability -$8.22K -986 -2.92% $8.34 32.8K Apr 17, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents options granted May 17, 2013, with a $2.94 strike price aand expiration of May 17, 2023.
F2 Represents shares automatically sold pursuant to a 10b5-1 plan to an irrevocable sell to cover election to satisfy tax withholding obligation in connectionwith the exercise of 1,700 shares from a May 2013 grant.